Tickwind
TodayOpportunitiesMarketsAI Chat
EN
Log inSign up
Tickwind

Read every tick. See where the market's blowing.

  • X
  • TelegramChinese
  • Newsletter

Product

  • Markets
  • Theme Zones
  • All stocks
  • Compare
  • Hot stocks
  • Opportunities
  • News
  • Discussion
  • Watchlist
  • What's new

Account

  • Settings
  • Newsletter
  • For writers
  • MCP server
  • Contact
  • Log in
  • Sign up
MarketsTheme ZonesAll stocksCompareHot stocksOpportunitiesNewsDiscussionWatchlistWhat's newSettingsNewsletterFor writersMCP serverContactLog inSign up

© 2026 Tickwind. Not investment advice.

Made for the curious investor.

Home/GRCE/Revenue

Grace Therapeutics, Inc. (GRCE) Revenue 2022–2023

Grace Therapeutics, Inc. (GRCE) annual revenue history from SEC filings — each fiscal year as reported, with year-over-year change.

$100.0MFY2023 · since FY2022: $196,000 → $100.0M
2223
Fiscal yearValueYoY
FY2023$100.0M+50920.4%
FY2022$196,000—

Source: SEC XBRL filings · For reference only · Not investment advice

More GRCE financial trends

GRCE Net incomeGRCE Net marginGRCE Gross profitGRCE Gross marginGRCE Operating incomeGRCE Operating marginGRCE Operating cash flowGRCE Free cash flowGRCE Capital expendituresGRCE Return on equityGRCE Stock buybacksGRCE Dividends paidGRCE Total assetsGRCE Total liabilitiesGRCE Shareholders’ equityGRCE overview →